Mabylon AG
Niccolo Pengo currently serves as the Chief Scientific Officer and Head of B-cell technologies at Mabylon AG since April 2019. Prior to this role, Niccolo worked as a Senior Scientist in the antibody discovery group at UCB from March 2016 to March 2019. Niccolo's academic background includes a Postdoctoral Research Associate position at University College London, where leadership was provided on a project focused on the signaling control of autophagy in mammalian cells. Previous research experience includes a PhD candidacy at San Raffaele Biomedical Science Park, concentrating on immunology and cancer biology, along with an undergraduate stage at the University of Geneva studying genetic mutations related to hemostasis diseases. Niccolo holds a PhD and an MSc in Molecular Biology from Libera Università Vita-Salute San Raffaele.
This person is not in any teams
This person is not in any offices
Mabylon AG
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.